Alzai Health signs MOU with Quanterix to explore early Alzheimer's identification collaboration
QTRX•Alzai Health and Quanterix signed a primarily nonbinding MOU on November 13, 2026, to explore combining AI-driven risk identification with Quanterix's LucentAD blood-based biomarkers. Any future commercial arrangements require separate definitive agreements.
1. Proposed collaboration
The companies said they would explore combining Alzai Health's AI-driven risk identification technology with Quanterix's LucentAD blood-based biomarkers to support targeted diagnostic testing. The MOU is primarily nonbinding, and future commercial arrangements require separate definitive agreements.
